

# Harnessing the power of HMOs to deliver advanced gut care throughout life

GLYCARE® Human Milk Oligosaccharides\*

The next generation nutrient supporting gut health for the dietary supplements market.



\*not from human milk

dsm-firmenich 



## Consumer demand for gut health is on the rise

Driven by lifestyle disruptions in a fast-paced, ever-changing world, consumers are seeking digestive health solutions more than ever. And most consumers want to support and improve their gut health through diet and supplements. This strong consumer pull creates an opportunity for brands to leverage emerging science to bring new and innovative gut health solutions.



Consumer **interest in gut health has increased threefold** in the last five years<sup>1</sup>



aim to **eat foods that encourage a healthy microbiome**<sup>2</sup>



are interested in **products that enhance digestion**<sup>2</sup>



said they'd **purchase a dietary supplement with HMOs** after learning about their health benefits<sup>3</sup>



## Differentiate your next gut health innovation

HMOs are unique, gut-strengthening nutrients found in infant nutrition, scientifically shown to better equip the gut and thus support immune function, digestive health and an active lifestyle.<sup>4</sup>

While the utilization of HMOs in infant formula and food products is a recent innovation, HMOs have been scientifically studied for over 130 years. Thanks to advancements in science, the gut-strengthening benefits of HMOs can now be leveraged throughout life!




## dsm-firmenich GLYCARE® HMOs do more to build a stronger gut

dsm-firmenich is pioneering the oligosaccharides market with GLYCARE® HMOs by delivering innovations for all of life's ages and stages and enabling consumers to do more to stay healthy, active and resilient throughout life.

dsm-firmenich GLYCARE® HMOs help build a **stronger gut** through **Triple Action**:



Selectively feeds **good bacteria** so they can flourish



Fosters a thriving **community** in the gut from the very start



Builds a sturdier **house** for good bacteria to live

**Plus... they support the role of probiotics in the gut by both nourishing and protecting good bacteria.<sup>4</sup>**

Uniquely designed to mimic the bioactive components of breastmilk, dsm-firmenich GLYCARE® HMOs are the building blocks for optimal digestive health, immunity and active nutrition. They also feature key attributes that today's consumers seek:



Clean label



Gluten free



Vegetarian



Kosher



Allergen free\*\*



FODMAP diet friendly

\*\* Except milk

## The most comprehensive HMO portfolio worldwide

With the broadest commercial HMO portfolio in the market, GLYCARE® HMOs are nature-identical, suitable for a wide variety of applications, and carry a **5-year shelf life**.

The portfolio offers science-backed health benefits across a wide range of products. This is based on scientific exploration around three key areas of human health: gut, brain, and immune health.

GLYCARE® HMO portfolio								
Health benefit	2FL	3FL	2FL/ DFL	LNFP-I	3SL	6SL	LNnT	LNT
Gut health	●	●	●	●	●	●	●	●
Immune health	●	●	●	●	●	●	●	●
Brain health	●	●	●	●	●	●	●	●

● Clinical data in adults

● No or limited mechanistic data

● Observational and/or wide variety of mechanistic data

## Leading the way with regulatory approvals

We are leading the number of global regulatory approvals on HMOs and are continuously expanding our global footprint to make HMOs easily available to our partners. Six single-ingredient or blend HMOs are currently authorized as Novel Foods in the EU and are notified to the U.S. FDA as GRAS, with more to come from our innovation pipeline.

HMO	GRAS Notice	Intended Use	GRAS Uses
2'FL	650	Children † Adults	Children's formulas: 2.4 g/L Beverages: Up to 5 g/L Foods: Up to 40 g/kg
LNnT	659	Children † Adults	Children's formulas: 0.6 g/L Beverages: Up to 2.5 g/L Foods: Up to 20 g/kg
3'SL	880	Children † Adults	Children's formulas: 0.15–0.20 g/L Beverages: Up to 0.5 g/L Foods: Up to 5 g/kg
6'SL	881	Children † Adults	Children's formulas: 0.3–0.4 g/L Beverages: Up to 1.0 g/L Foods: Up to 10 g/kg
2'FL/DFL	815	Children † Adults	Children's formulas: 1.2–1.6 g/L Beverages: Up to 4 g/L Foods: Up to 40 g/kg
LNT	833	Children † Adults	Children's formulas: 0.6 g/L Beverages: Up to 2.0 g/L Foods: Up to 20 g/kg

† Ages 3+

## Expanding the possibilities around applications

Completed work with 2FL and LNnT includes:

- Fast dissolving tablet<sup>††</sup>
- Gummies<sup>††</sup>
- Soft chew<sup>††</sup>
- Stick pack<sup>††</sup>
- Chewable tablets<sup>††</sup>
- Beverages, medical nutrition, and more

<sup>††</sup> Patent filed. Country-specific







dsm-firmenich is the only HMO provider that has a fully integrated and dedicated HMO production site that oversees the entire process – from product development, pre-clinical and clinical development, to regulatory and large-scale production. This allows us to make HMOs easily available to you, and to support you in getting to market with customer- focused science-backed quality and safety at the core.

## dsm-firmenich: Your innovative end-to-end partner in HMOs

### Widest Portfolio with Legacy of Trust

With the widest portfolio of commercially available HMOs, our extensive history provides assurance of quality as a trusted source for infants, children, and adults

### Expert Services to Support your Product Development

We can support your product launch with expertise in innovation and R&D, application development, regulatory and legal advice, scientific support and insights and marketing

### Long shelf life and high purity

GLYCARE® HMOs feature **dry blend powder properties, longest shelf-life (5 years), and high purity**

### Streamline your product development process

The only **manufacturer** of HMOs with **straight, premix capabilities and market-ready solutions** under one roof

### Largest market access – world's largest HMO facility

Available for use in more than 165 countries, the **largest market access** for HMOs worldwide, and in supply with the **world's largest HMO facility**

### Pioneering the future of HMOs

Together with clinical partners, leading universities and external labs, **we have supported over 20 studies** to advance the understanding of HMOs and how they impact human health

1 Google analytics

2 Lightspeed/Mintel; KuRunData/Mintel

3 Qualtrics Custom HMOs Survey, November 2020. n=417

4 (Elison 2016) Elison E, Vigsnaes LK, Rindom Krogsgaard L, et al. Oral supplementation of healthy adults with 2'-O-fucosyllactose and lacto-N-neotetraose is well tolerated and shifts the intestinal microbiota. *Br J Nutr.* 2016;116(8):1356-1368

5 (Illiano 2020). Illiano P, Brambilla R, Parolini C. The mutual interplay of gut microbiota, diet and human disease. *Febs j.* 2020;287(5):833-855

6 (Iribarren 2020). Iribarren C, Törnblom H, Aziz I, et al. Human milk oligosaccharide supplementation in irritable bowel syndrome patients: A parallel, randomized, double-blind, placebo-controlled study. *Neurogastroenterol Motil.* 2020;32(10):e13920

7 (Kunz 2012) Kunz C. Historical aspects of human milk oligosaccharides. *Adv Nutr.* 2012;3(3):430s-439s

8 (Bode 2012) Bode L, Jantscher-Krenn E. Structure-function relationships of human milk oligosaccharides. *Adv Nutr.* May 1 2012;3(3):383s-91s. doi:10.3945/an.111.001404

9 (Gibson 1994) Gibson GR, Wang X. Regulatory effects of bifidobacteria on the growth of other colonic bacteria. *J Appl Bacteriol.* Oct 1994;77(4):412-20. doi:10.1111/j.1365-2672.1994.tb03443.x

10 (Schwab 2017). Schwab C, Ruscheweyh HJ, Bunesova V, Pham VT, Beerenwinkel N, Lacroix C. Trophic Interactions of Infant Bifidobacteria and *Eubacterium hallii* during L-Fucose and Fucosyllactose Degradation. *Front Microbiol.* 2017;8:95

† As measured by the Bristol Stool Form Scale (BFBS)

‡ Based on the IBS Symptom Severity Score (IBS-SSS)

#### Disclaimer

Copyright © 2025 dsm-firmenich group.  
www.dsm-firmenich.com. All rights reserved.

dsm-firmenich has used diligent care to ensure that the information provided herein is accurate and up-to-date to the best of its knowledge. However, dsm-firmenich makes no representation or warranty, either expressly or implied, of the accuracy, reliability, completeness, or suitability thereof. The information provided herein contains scientific and product information for business-to-business use and does not constitute or provide scientific or medical advice, diagnosis or recommendation for treatment options. Country or region-specific information should be considered when labelling or advertising to final consumer. In no event shall dsm-firmenich be liable for any direct or indirect damages arising from or reliance upon, or use of, any information provided herein. The content of this document is subject to change without further notice. Please contact your local dsm-firmenich representative for the latest information. All trademarks listed in this document are either (registered) trademarks of, or trademarks licensed by, the dsm-firmenich group of companies, unless explicitly stated otherwise.